Dentsply Sirona: 3 Key Takeaways for Long-Term Investors
Dentsply Sirona lowered its full-year 2026 sales guidance to $3.5 billion and reduced adjusted EPS to $1.20-$1.30 due to weakness in dental equipment demand and higher distribution costs. The company is investing heavily in clinical education programs in North America and building sales teams for dental support organizations. Wellspect Healthcare showed positive momentum with 10% revenue growth to $92 million, while management prioritizes debt reduction alongside disciplined reinvestment in commercial execution.


